Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML)

Leukemia

Volumn 16, Issue 5, 2002, Pages 833-839

  Van Den Heuvel Eibrink, M M ^a,b   Wiemer, E A C ^a   Prins, A ^a   Meijerink, J P P ^b   Vossebeld, P J M ^a   van der Holt, B ^a   Pieters, R ^b   Sonneveld, P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

AML; BCRP MXR ABCP; LRP MVP; MDR1; MRP1; Relapse

Indexed keywords

ABC TRANSPORTER; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; IDARUBICIN; LUNG RESISTANCE PROTEIN; MEMBRANE PROTEIN; MESSENGER RNA; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PLACENTA PROTEIN; PROTEIN BCRP; RNA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; GENETIC CODE; HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS;

EID: 0036100195     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402496     Document Type: Article

References (67)

1. The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia
2. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis
3. Prognostic value of cell marker analysis in de novo acute myeloid leukemia
4. Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: A report from the Childrens Cancer Group
5. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia
6. P-glycoprotein expression in patients with acute leukemia-clinical relevance
7. MDR-1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia
8. Multidrug resistance gene expression in acute myeloid leukemia: Major prognostic significance for in vivo drug resistance to induction treatment
9. P-glycoprotein expression in de novo acute myeloid leukemia
10. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: Studies of the Southwest Oncology Group Leukemia Research Program
11. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival
12. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia
13. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia
14. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome
15. Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase IIalpha) in 57 newly diagnosed acute myeloid leukaemias
16. Expression of the human major vault protein LRP in acute myeloid leukemia
17. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy
18. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients
19. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia
20. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: Biological and clinical implications
21. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line
22. A multidrug resistance transporter from human MCF-7 breast cancer cells
23. Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines
24. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes
25. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR
26. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance
27. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia
28. Novel mechanisms of drug resistance in leukemia
29. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients
30. The role of MDR1 gene related clonal selection and P-gp function and expression in the development of AML towards relapsed/refractory disease
31. Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: Results of molecular and functional assays, and correlation with treatment outcome
32. Increased P-glycoprotein expression and multidrug-resistant gene (mdr1) amplification are infrequently found in fresh acute leukemia cells. Sequential analysis of 15 cases at initial presentation and relapsed stage
33. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia
34. Proposed revised criteria for the classification of acute myeloid leukemia
35. Six months of intensive chemotherapy for childhood ANLL; preliminary results of the study ANLL87 of the DCSLG
36. Results of DCLSG protocol ANLL94, BFM oriented intensive chemotherapy, followed by allogeneic or autologous bone marrow transplantation
37. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia
38. A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR
39. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16
40. Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody
41. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells
42. Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123
43. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein
44. The mouse Bcrp1/Mxr/Abcp gene: Amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin
45. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein
46. Isolation and characterization of a mammalian homolog of the Drosophila white gene
47. ABC transporters involved in transport of eye pigment precursors in Drosophila melanogaster
48. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group Study
49. In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells
50. Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines
51. High levels of lung resistance related protein mRNA in leukaemic cells from patients with acute myelogenous leukaemia are associated with inferior response to chemotherapy and prior treatment with mitoxantrone
52. Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia
53. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia
54. Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells
55. Expression of mdr1, mrp, topoisomerase II alpha/beta, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias
56. Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML
57. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia
58. Clinical relevance of immunocytochemical detection of multidrug-resistance-associated P-glycoprotein in hematologic malignancies
59. Multidrug resistance (mdr1) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity
60. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations
61. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry
62. Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia
63. Mdr-1 gene amplification in acute lymphoblastic leukaemia prior to antileukaemic treatment
64. P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival
65. MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia
66. Daunorubicin uptake by leukemic cells: Correlations with treatment outcome and mdr1 expression